Home » Topics » BioWorld Science, Nephrology

BioWorld Science, Nephrology
RSS

Orally active nonpeptide aquaretic V2 antagonist advanced to human testing

Aug. 25, 2004

Yamanouchi and Boehringer Ingelheim to copromote Flomax in U.S. for BPH

Aug. 18, 2004

Yentreve approved in E.U. for stress urinary incontinence

Aug. 18, 2004

Sanctura distribution under way

Aug. 17, 2004

Good efficacy and safety shown for long-term use of Sanctura

Aug. 4, 2004

European approval recommended for Emselex

Aug. 3, 2004

Further positive phase I/II data for NX-1207 in BPH

Aug. 2, 2004

Chinese researchers identify novel agents for renal disorders

July 30, 2004

Novel dopamine D3 agonists and their use in sexual disorders

July 29, 2004

INNOVATION study of Micardis completes enrollment

July 28, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal
BioWorld
In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Roche secures CE mark for Alzheimer’s blood test
BioWorld
Roche Holding AG secured CE marking for the Elecsys plasma phosphorylated-tau 217 blood test designed to rule in and rule out amyloid pathology, a hallmark of...